Andere talen Mainstay Medical International

Aandelen

MSTY

IE00BJYS1G50

Real Time Euronext Paris Andere beurzen			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
- ^EUR	-.--%		-10,55%	-42,65%

12/03	Mainstay Medical Holdings plc kondigt de publicatie aan van klinische resultaten waarin oudere patiënten worden vergeleken met jongere patiënten	CI
12/02	Mainstay Medical kondigt FDA-goedkeuring aan voor MRI-labeling op Reactiv8® Restorative Neurostimulation Systemtm	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Mainstay Medical Holdings plc Announces Publication of Clinical Results Comparing Older Patients and Younger Patients	12/03
Mainstay Medical Holdings plc announced that it has received ?115 million in funding from a group of investors	26/02
Mainstay Medical Holdings plc announced that it expects to receive funding	23/02
Mainstay Medical Announces Receipt of FDA Approval for MRI Labeling on Reactiv8® Restorative Neurostimulation Systemtm	12/02
Mainstay Medical Announces Completion of Enrollment of RESTORE Clinical Trial of ReActiv8® in the United States	29-08-23
Mainstay Medical Holdings plc Announces Publication of Three-Year Clinical Trial Data from Post-Market Clinical Follow-Up Registry of Reactiv8 in the United Kingdom	20-07-23
Mainstay Medical Holdings plc Reports Earnings Results for the Full Year Ended December 31, 2022	28-03-23
Mainstay Medical Holdings plc Announces the Publication of Effect of Restorative Neurostimulation on Major Drivers of Chronic Low Back Pain Economic Impact	02-03-23
Esker : Midcap Partners débute le suivi à Achat	06-12-22
Mainstay Medical Announces Publication of Post-Market Clinical Trial Data from Ongoing ReActiv8®-C Study in Chronic Low Back Pain Patients	22-11-22
Mainstay Medical Holdings plc Reports Earnings Results for the Full Year Ended December 31, 2021	28-03-22
Mainstay Medical Holdings plc Announces Publication of Two-Year Patient Outcomes Data from Reactiv8-B Clinical Trial Demonstrating Long-Term Efficacy of Reactiv8 Restorative Neurostimulation	06-01-22
Mainstay Medical Holdings plc Announces Appointment of Jeffrey Dunn and Eric Major to Its Board of Directors	14-12-21
Mainstay Medical Holdings plc Reports Earnings Results for the Full Year Ended December 31, 2020	09-07-21
Mainstay Medical Announces Limited Announces Commercial Launch of ReActiv8® in US	29-06-21
Oxford Finance LLC Announces Closing of $50 Million Senior Secured Term Loan with Mainstay Medical Holdings plc	20-04-21
Mainstay Medical Announces Commercial Launch of ReActiv8® in Australia	08-03-21
Mainstay Medical Holdings plc announced that it has received $108 million in funding from Ally Bridge Group, KCK Group, Sofinnova Partners SAS, Fountain Healthcare Partners, and another investor	16-02-21
Mainstay Medical Holdings plc announced a financing transaction	09-02-21
Mainstay Medical Holdings plc Announces U.S. FDA Approval of ReActiv8® Neurostimulation System for Chronic Low Back Pain	22-06-20

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Mainstay Medical International

Aandelen

MSTY

IE00BJYS1G50

Andere talen

Filters